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Abstract
The literature dealing with mathematical modelling for diabetes is abundant. During the last
decades, a variety of models have been devoted to different aspects of diabetes, including glucose
and insulin dynamics, management and complications prevention, cost and cost-effectiveness of
strategies and epidemiology of diabetes in general. Several reviews are published regularly on
mathematical models used for specific aspects of diabetes. In the present paper we propose a global
overview of mathematical models dealing with many aspects of diabetes and using various tools.
The review includes, side by side, models which are simple and/or comprehensive; deterministic
and/or stochastic; continuous and/or discrete; using ordinary differential equations, partial
differential equations, optimal control theory, integral equations, matrix analysis and computer
algorithms.
Introduction
It is now commonly admitted that diabetes is sweeping
the globe as a silent epidemic largely contributing to the
growing burden of non-communicable diseases and
mainly encouraged by decreasing levels of activity and
increasing prevalence of obesity [1-5]. Dramatic increase
has occurred in both prevalence and incidence of diabe-
tes, especially with the new threshold proposed by the
Expert Committee on the diagnosis and classification of
diabetes mellitus in 1997 [6] and adopted by the World
Health Organization. During the last decades, a huge
number of papers were published on different aspects of
diabetes and its complications. In particular, an interest-
ing literature has been devoted to studies collecting, ana-
lyzing and validating data concerning diabetes
populations. A variety of mathematical models, statistical
methods and computer algorithms have been proposed in
order to understand different aspects of diabetes such as:
glucose-insulin dynamics, epidemiology of diabetes and
its complications, cost of diabetes and cost-effectiveness
of strategies dealing with diabetes. Several reviews have
been devoted to mathematical models and diabetes. In
their majority, these reviews concentrated on specific
aspects of diabetes such as glucose-insulin dynamics [7-
13], computer algorithms and devices [14-16], sensors
and control [17,18], mathematical and software aspects
[19], glycemic index [20], burden and cost of diabetes
[21,22]. On the one side, it is difficult to include in one
review mathematical models published on different
aspects of diabetes. On the other side, it would be very
useful for researchers in this field to get a panorama of the
models published so-far and their references. The benefit
will be greater if such a review is published with free
online access, especially for physicians and researchers in
developing countries. The challenge is worth trying and
the present paper is proposing a non-exhaustive overview
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including model structure, computer algorithms, data
used as input and model validation.
Glucose-insulin dynamics
Mathematical models
The majority of mathematical models proposed in the lit-
erature were devoted to the dynamics of glucose-insulin,
including Intra Venous Glucose Tolerance Test (IVGTT),
Oral Glucose Test (OGTT), Frequently Sampled Intrave-
nous Glucose Tolerance Test (FSIGT). In 1939,
Himsworth and Ker [23] introduced the first approach to
measure the insulin sensitivity in vivo. Mathematical mod-
els have been used to estimate the glucose disappearance
and insulin-glucose dynamics in general. Bolie is among
the pioneers in this field. In 1961, using ordinary differen-
tial equations, he proposed the following simple model
[24]:
where G = G(t) represents the glucose concentration, I =
I(t) represents the insulin and p, a1, a2, a3, a4 are parame-
ters.
Although various models (simple and comprehensive)
were proposed by different authors [25-28] (see also the
244 references in the review by Bergman et al. (1985)) [7],
especially those dealing with insulin sensitivity, the real
start of modeling the glucose-insulin dynamics is thought
to begin with the so-called minimal model proposed by
the team of Bergman and Cobelli in the early eighties
[29,30]. The model was formulated as follows:
where, (G(t) - p5)+ = G(t) - p5 if G(t) > p5 and 0 otherwise.
X(t) denotes an auxiliary function representing insulin-
excitable tissue glucose uptake activity, Gb, and Ib are the
subject's baseline glyceamia and insulinimia. b0 – b7 are
parameters. It should be stressed that, although equations
(3)–(5) were developed for describing FSIGT data, these
equations were presented into two parts. Part 1 with equa-
tions (3)–(4) and part 2 using equation (5). A large
number of papers have been published, using modified
versions of the glucose minimal model (3)–(4) for
describing OGTT and meal tests, while insulin minimal
models derived from (5) are still limited to IVGTT. It
should also be stated that the major contribution of the
glucose minimal model (3)–(4) has been to provide
means of estimating insulin sensitivity SI = p3/p2, avoid-
ing the glucose clamp.
The same authors have further published papers, complet-
ing, testing or validating the results of the minimal model
[7,31-33]. An indication of the importance of the mini-
mal model and subsequent research for diabetes under-
standing is given by the 2006 Banting medal awarded by
the American Diabetes Association to Professor Bergman
for his achievements.
Variant versions based on the minimal model were con-
sidered by different authors. An example of this category
was proposed by Derouich and Boutayeb who used a
modified version of the minimal model to introduce
parameters related to physical exercise [34]:
where q1, q2, q3 are parameters related to physical activity
and defined as follows:
q1 : the effect of physical exercise in accelerating the utili-
zation of glucose by muscles and the liver insulin
q2 : the effect of physical exercise in increasing the muscu-
lar and liver sensibility to the action of insulin.
q3 : the effect of physical exercise in increasing the utiliza-
tion of insulin. In other words, q3 increases insulin effec-
tiveness in enhancing glucose disposal and consequently
improving insulin sensitivity to become: SI = (p3 + q3)(1 +
p2)/P2.
According to a paper published by Bergman in 2002 [35],
more than 500 studies related to the minimal model can
be found in the literature. More information on this his-
toric model and related models can be found in literature
[8,9].
However, some authors [19,36-38] indicated that while
the minimal model has minimal number of constants (p0-
p7), and has been indisputably useful in physiological
research, it has the following drawbacks:
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1. The model, as originally proposed, is to be regarded as
composed of two separate parts. The first part uses equa-
tions (3) and (4) and the second part uses equation (5).
For the last part, plasma glucose concentration is to be
regarded as a known forcing function. In other words, the
model parameter fitting has to be conducted in two steps:
first, using the recorded insulin concentration as input
data in order to derive the parameters in the two first
equations, then using the recorded glucose as input data
to derive the parameters in the third equation.
2. Some of the mathematical results produced by this
model are not realistic(problems of positive equilibrium
and solutions not bounded).
3. The artificial non-observable variable X(t) is introduced
to take account of the delay in the action of insulin.
Taking into account these remarks and stressing that the
glucose-insulin system is an integrated physiologic
dynamical system which should be dealt with as a whole,
De Gaetano and Arino [36,37] proposed an aggregated
delay differential model called a dynamical model:
After renaming the parameters, the dynamical model
takes the form [36]:
with G(t) = Gb for -b5 ≤ t < 0
Mukhopadhyay et al. (2004) recalled that this model has
been shown to allow simultaneous estimation of both
insulin secretion and glucose uptake parameters, to have
positive, bounded solutions, and to be globally asymptot-
ically stable around the pre-injection equilibrium blood
glucose and insulin concentrations. They proposed an
extension by introducing a generic weight function ω in
the delay integral kernel for the pancreatic response to glu-
cose. The new model obtained is as follows:
with G(t) = Gb for t < 0
A more general model was proposed by Li et al. (2001).
The authors noted that, while the dynamical model solves
the problems of the minimal model, it implicitly or
explicitly made a few assumptions that may not be neces-
sary or realistic. Specifically, some of the interaction terms
are too special and thus too restrictive. For example, the
term b4I(t)G(t) assumes that mass action law applies here
while a more popular, general and realistic alternative is
to replace this term by b4I(t)G(t)/(αG(t) + 1). The way the
delay is introduced is also restrictive. Consequently, the
model proposed is the following:
with G(t) = Gb for -b5≤ t <0 and Gt(θ) = G(t + θ), t > 0, -b5
≤ θ < 0.
Other models of the glucose-insulin dynamics, using opti-
mal control or partial differential equations were pro-
posed by different authors [18,40-44]. Cobelli and
Tomaseth [41] discussed the optimal input design in a
model of glucose kinetics. They proposed the following
model:
y(t) = c(p)x(t)   (15)
z(t) = y(t) + e(t)   (16)
h [x(t), u(t), p] ≥ 0   (17)
Lam et al. [44] used a slightly modified version of the
minimal model for the assessment of insulin sensitivity.
An interesting survey of mathematical models using con-
trol for glucose-insulin and management of diabetes is
given by Palerm in his Ph. D thesis, with some 350 refer-
ences [18]. The author focussed on the Direct Model Ref-
erence Adaptive Control (DMRAC) and its reformulation.
The formulation of the general DMRAC algorithm is
based on the following system
or more generally,
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where x(t) is the (nx1) state vector, u(t) is the (mx1) con-
trol vector, y(t) is the (qx1) output vector, A, B, C and D
are matrices with appropriate dimensions. The objective is
to find, without explicit knowledge of A and B, a control
u(t) such that the output vector y(t) fellows a reference
model.
Computer algorithms
The regulation of blood glucose concentration is mainly
achieved by acting on three control variables: insulin,
meals and physical exercise. However, as stressed by
Bellazzi et al. [15], the quantitative evaluation of meals
and physical effort still represents a major problem in
home monitoring. Consequently, the quasi totality of
proposed control systems have focused on insulin therapy
strategies. A number of devices-microsystems and compu-
ter approaches- have been reported in the literature with
open, closed and partially closed algorithms, Selam and
Charles [45], Lehman and Deutsch [46,47]. Two reviews
on the intravenous route to blood glucose control and
subcutaneous route to insulin dependent diabetes therapy
were recently published by Bellazzi et al. [15] and Parker
et al. [16]. A partial list of software packages, commer-
cially and freely available is given in a recent review by
Makroglou et al. [19].
The closed-loop strategy
An example of models with closed-loop strategy is a wear-
able artificial pancreas as proposed by Shimoda et al.
[18,48], based on the assumption that the relationship
between plasma insulin and blood glucose concentration
in a normal subject during an oral glucose bolus is as fol-
lows:
where I denotes the plasma insulin concentration; G is the
blood glucose concentration; and a, b and c are parame-
ters that can be estimated by nonlinear least squares
method [49].
The insulin dynamics is described by the following ordi-
nary differential system:
where V is the plasma volume, IIR represents the Insulin
Infusion Rate; X, Y and Z are the insulin masses in the two
subcutaneous compartments and in plasma respectively.
The open-loop approach
According to the review by Bergman et al. [7], two distinct
classes of methodologies were applied to open the glu-
cose/insulin feedback relationship in vivo. The first
method pioneered by Reaven and his colleagues [50], and
labelled as the pancreatic or insulin suppression test, uti-
lized pharmacologic means to render the pancreas blind
to plasma glucose concentration. The second approach,
labelled as the glucose clamp, was proposed by Andres
[51]. The method uses a variable glucose infusion to
establish a relatively constant plasma glucose concentra-
tion with or without exogenous insulin. Mathematical
models are also proposed to deal with the deterioration of
beta-cell [52-54].
Epidemiological models applied to diabetes
Historically, since the first model of smallpox formulated
by Bernoulli in 1760, an abundant literature was devoted
to mathematical models dealing with communicable dis-
eases such as measles, rubella, malaria, influenza, AIDS,
dengue and others [56]. As indicated by a review pub-
lished by Hethcote in 2000 [57], a tremendous variety of
models have been formulated, mathematically analyzed,
and applied to infectious diseases. Modelling has thus
become an interesting tool providing conceptual results
such as thresholds, basic reproduction numbers, contact
numbers, and replacement numbers. Application of simi-
lar models for non communicable diseases is rather unu-
sual. In this way, few authors have proposed
epidemiological models for diabetes and obesity [58-66].
In [59], Boutayeb and Derouich considered two discrete
models for the evolution from diabetes without complica-
tions to the stage of diabetes with complications.
In [60], using partial differential equations, the authors
proposed an age structured continuous model for compli-
cations of diabetes. Supposing that C = C(a, t) and D =
D(a, t) represent the numbers of diabetics with and with-
out complications aged a at time t, respectively, and n(a,
t) = C(a, t) + D(a, t) the size of the population of diabetics
aged a at time t, different scenarios with different values
were used for the following parameters: natural death rate
(d(a, t)), death rate due to complications (δ(a, t)), inci-
dence of diabetes with and without complications (I1(a,
t)), (I2(a, t)) rate at which complications are developed
(p(a, t)) and rate at which complications could eventually
be cured (q(a, t)). The main objective of the authors was
It a Gt b
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to show that, although diabetes is not curable at the
moment, prevention of its complications (which is possi-
ble) would improve peoples quality of life and reduce
costs of the national health and social services. Assuming
that the number of males is equal to the number of
females and that diabetes affects the people of the two
sexes equally, the continuous age structured model is for-
malized by the following partial differential equations:
adding equations (25) and (26) and writing :
C(a, t) = r(a, t)n(a, t)   (27)
leads to
In the same spirit, Boutayeb and colleagues [62,63] pro-
posed linear and non-linear population models of diabe-
tes mellitus, using ordinary differential equations and
numerical implementation.
Data analysis, parameters estimation and 
validation
Studies and trials
Worldwide, different studies were devoted to diabetes and
its complications. These studies have been used directly or
indirectly for data analysis, mathematical modeling and
parameters validation. Among the most cited studies, Dia-
betes Control Complications Trial (DCCT) [67] and UK
Diabetes Prevention Study (UKPDS) [68]. The first trial
involved 1,441 volunteers with type 1 diabetes and 29
medical centers in the United States and Canada, and
have shown that, diabetes complications can be reduced
or at least delayed by a good regular glycemic control
through intensive insulin therapy consisting of three or
more insulin injections per day or in the use of insulin
pumps. The main DCCT Study Findings were the follow-
ing: Lowering blood glucose reduces the risks of eye dis-
ease, kidney failure and nerve disease by 76%, 50% and
60% respectively [69-72]. The second trial concerned over
5000 non insulin-dependent patients from 23 centres
from all parts of England, Scotland and Northern Irland,
showing that complications of diabetes can be prevented
by a better control of blood glucose and blood pressure.
Among the 70 papers published by the UKPDS group, we
cite here some of those using mathematical models. The
UKPDS risk engine was used as a model for the risk of cor-
onary heart disease, myocardial infarctus and stroke in
Type II diabetes [73-75]. Modeling glucose exposure as a
risk factor for photocoagulation in Type II diabetes was
considered in [76], whereas the UKPDS Outcomes Model
was proposed to estimate the lifetime health outcomes of
patients with Type 2 [77]. Data collection, parameters esti-
mation and validation concerned a multitude of other
studies such as: the Wisconsin epidemiologic study of dia-
betic retinopathy (WESDR) [78], Framingham Heart
Study (FHS) [79], Diabetes Prevention Program (DPP)
[80], Health Outcomes Prevention Evaluation (HOPE)
[81,82], The Health Plan Employer Data and Information
Set (HEDIS) [83], Echantillon national temoin représent-
ant des personnes diabétiques (ENTERED) [84], Multiple
Risk Factor Intervention Trial (MRFIT) [85], Heart Protec-
tion Study (HPS) [86], Cholesterol and Recurrent Events
(CARE) [87], ACE Inhibitors and Diabetic Nephropathy
Trial (Lewis) [88], the IRMA-2 trial [89], Irbesartan Dia-
betic Nephropathy Trial (IDNT) [90], the Collaborative
AtoRvastatin Diabetes Study (CARDS) [91].
The archimedes model
According to [92], until recently, there have been four
main kinds of mathematical models in health care:
1. Biological modeling,
2. Clinical Medicine,
3. Operations research,
4. Economic/system resources.
Thus, the authors present Archimedes as a new type of
mathematical model which includes all four components.
Archimedes is a very detailed, comprehensive, continuous
simulation model. A person-by-person, object-by-object
simulation, spanning from biological details to the care
processes, logistics, resources, and costs of health care sys-
tems [92-94]. The model is written in differential equa-
tions for which different levels of detail may be
considered [95]. The equations, assumptions, and sources
are summarised in an online appendix (available at http:/
/care.diabetesjournals.org). A validation of the
Archimedes model of diabetes and its complications or a
variety of populations, organ systems, treatments, and
outcomes is given by Eddy & Schlessinger [96,97]. The
model was validated against 18 trials of which ten trials
explicitly dealing with diabetes. Namely: the Diabetes
Control and Complications Trial(DCCT) [67], the U.K.
Prospective Diabetes Study (UKPDS) [68], the Diabetes
Prevention Program (DPP) [80], the Health Outcomes
Prevention Evaluation (HOPE) [81], the diabetes sub-
population of the HOPE Trial (Micro-HOPE) [82], the
Heart Protection Study (HPS) [86], Cholesterol and
∂
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Recurrent Events (CARE) [87], the ACE Inhibitors and
Diabetic Nephropathy Trial (Lewis) [88], the IRMA-2 trial
[89], and the Irbesartan Diabetic Nephropathy Trial
(IDNT) [90]. In general, between 10 and 30 equations are
needed to represent the pathophysiology of the disease
and calculate the effect of a specific treatment on a specific
outcome in a specific population (not included equations
for behaviors, care processes, logistics, and other nonbio-
logical aspects of the model. As stressed by the Editorial of
Diabetes Care [98], functional forms of the equation are
given but values of the variables and parts of the model
that describe micro- and macro-vascular complications
are not provided. However, beyond these limitations, the
model was used to predict 74 major outcomes, giving
astounding results: In 71 out of the 74 clinical outcomes,
the differences between the results calculated by the
model and the observed ones were statistically not signif-
icant. More information on Archimedes model can be
found in [92].
Other models
Other models and computer algorithms were devoted to
the burden, cost and cost-effectiveness of diabetes [99-
101], telemedicine and home management of diabetes
[102-104]. In a case study paper [104], Wu proposed the
following model for self-management of Type 2 diabetes:
where x represents blood glucose level over the baseline at
time t and ω0 is the system natural frequency. Finally, in
some papers and letters, mathematical models and guide-
lines for computer modeling of diabetes were subject to
debate and criticism [105-107].
Discussion
Mathematical models constitute interesting tools for the
understanding of diseases. They provide insights, improve
intuitions, clarify assumptions for formal theory, allow
for planning studies, estimating parameters, determining
sensitivities, assessing conjectures, simulating simple and
complex phenomena and providing future predictions. In
the case of diabetes, simple and comprehensive models
dealing with different aspects of the disease, have been
used during the last three decades. In general, simple
models are so simple as to be inadequate but they have
the advantage of using a small number of identifiable
parameters. Comprehensive models on the other hand are
models which try to represent the system (biological, clin-
ical, economic, etc...) by taking into account all interac-
tions. This makes them very complex and generally not
identifiable. In the present paper, our main objective was
an overview of models and studies dealing with different
aspects of diagnosis, care and management of diabetes
and its complications. We presented a non exhaustive list
of published models with their theoretical and applied
aspects, indicating what were the hypotheses that lead
authors to propose new, modified, generalized or alterna-
tive models. But we must say that we did not intend to
compare all models or classify them according to what-
ever criterion of performance. Even when available mod-
els are simple, they are not necessary comparable. For
instance, Bolie's model [24] is one of the simplest models
proposed to estimate the linear glucose disappearance
and insulin-glucose dynamics. However, since the author
is one of the pioneers in this field, his work remains an
unavoidable reference. Another very simple model was
recently proposed in a case study by Wu [104] but the pur-
pose was a self-management of type 2 diabetes. The model
being a case study based on a single type 2 diabetes per-
son, the results yielded need to be considered with cau-
tion. The discrete matrix model considered by Boutayeb
and Derouich [59] is also simple but the approach is com-
pletely different since it deals with the control of compli-
cations Bergman et al. [7] discussed seven models before
selecting the " best one" which became from then the well
known minimal model (between simple inadequate and
comprehensive not identifiable models), they based their
selection on the following criteria:
1. to be physiologically based,
2. having parameters that can be estimated with a reason-
able precision,
3. parameters with values that are reasonable and have
physiological interpretation,
4. best able to simulate the dynamics of the system with
smallest number of identifiable parameters.
In section 2, variant versions of the minimal model were
considered by different authors. For instance, in Derouich
and Boutayeb [34], physical exercise was seen to be an
interesting tool that improves insulin sensitivity (SI = (p3 +
q3)(l + p2)/p2)). The authors stressed that new control
strategies take a long time before they become affordable
on a large scale, especially in developing countries where
the majority of diabetics are struggling just to get insulin
doses and where the price of a blood strip exceeds the
individual income.
As indicated earlier, the minimal model has been indis-
putably useful in physiological research and served as
starting point for many other models. The drawbacks
raised by De Gaetano and Arino [36] were mainly based
on the mathematical formulation (specifically problems
of positive equilibrium and solutions not bounded). But
they stressed that no criticism is implied regarding the
dx
dt
dx
dt
xf t
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practical usefulness of the minimal model. By the way,
they acknowledge that their group uses the minimal
model in the routine evaluation of insulin sensitivity in
clinical patients. The so-called "dynamic model" pro-
posed by the previous authors has not escaped from criti-
cism since the assumptions made were judged to be not
necessary or realistic. This judgement was made by Li et al.
[38] who also criticised the restrictive way of using the
delay and proposed a more general model. According to
these authors, their general model was constructed for the
study of IVGTT which focuses on the metabolism of glu-
cose. However, except simulation and mathematical
aspects (steady state, oscillatory glucose and insulin lev-
els), no evidence is given on the real performance. For
computer algorithms, as stressed earlier, the quasi totality
of proposed control systems have focused on insulin ther-
apy strategies. In many cases, the proposition of models
are dictated by commercial purposes and the accessibility
to their pragmatic use remains restrictive. Finally, among
complex comprehensive models, Archimedes model can
be seen as the most illustrative. The huge arsenal of com-
puter and mathematical tools used by this model seems to
be justified by the first validated results. However, the
model has been published recently and more time is
needed to get sufficient information for a critical discus-
sion.
Conclusion
During the last decades, an interesting number of papers
have been published on mathematical models and com-
puter algorithms. In the present review, the authors have
tried to give a non-exhaustive panorama of the papers
which have used mathematical modeling for different
aspects of diabetes, including glucose-insulin dynamics,
beta-cell function, epidemiology of diabetes, manage-
ment and the burden of diabetes and its complications.
As indicated in section two, the award of 2006 banting
medal by the American Diabetes Association to Professor
Bergman for his achievements in diabetes research among
which, the famous minimal model, is an indication of the
importance of mathematical models for the understand-
ing of diabetes and its management.
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